Breaking the Therapeutic Ceiling in Schizophrenia Care

The introduction of muscarinic receptor agonism offers a new approach to schizophrenia treatment beyond traditional dopamine D2 receptor blockade. Listen in while Rebecca DePalma, DMSc, PA-C, explores the rationale behind targeting this new mechanism and emerging evidence for muscarinic therapies, with a focus on xanomeline/trospium. Through a discussion of efficacy, safety, and practical prescribing considerations, find out how these advances may apply to your practice and improve patient-centered care.

Presenter:Rebecca DePalma, DMSc, PA-C​Psychiatric Physician Associate​Doctorate of Medical Science​Adjunct Clinical Faculty, Pacific University​Co-Author of First Line Guide: Psychiatric and ​Behavioral Medicine​Seattle, Washington

Link to full program:https://bit.ly/4gvLZYm

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Neuroscience Podcast on Apple Podcasts, YouTube Music, or Spotify. 

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.